(Alliance News) - London's FTSE 100 ended little changed on Thursday, outperforming European peers, as investors weighed an as expected interest rate cut by the European Central Bank.

The London-based pharmaceutical company said Blenrep, or belantamab mafodotin, was approved for the treatment of adult patients with multiple myeloma in combination with bortezomib plus dexamethasone, ...